Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Lunit Cancer Screening logo — Lunit is a public company that develops medical AI software...

Lunit Cancer Screening

Lunit is a public company that develops medical AI software that helps conquer cancer globally.

Founded 2013 United States Seattle, United States 343 employees Post Ipo Debt Total: $405.58B AI, Analytics +4

General Information

Company Name Lunit Cancer Screening
Founded Year 2013
Location United States Seattle, United States +1
Founders / Decision Makers
Team member
Employees 343
Industries AI, Analytics, Computer Vision +3
Funding Stage Post Ipo Debt
Social

Get notified when Lunit Cancer Screening moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Lunit Cancer Screening

Lunit Cancer Screening is a trailblazer in the domain of medical AI, with a mission to "Conquer Cancer through AI". Founded in 2013, this United States-headquartered company has emerged as a leader in developing AI-driven software solutions specifically for cancer screening and treatment.

Lunit specializes in empowering healthcare professionals to significantly enhance diagnostic accuracy. Its flagship product suite, Lunit AI Suite for Radiology, features lauded innovations like Lunit INSIGHT CXR for chest x-rays, and Lunit INSIGHT MMG for mammography, validated in over 100 peer-reviewed publications. The company's technology is currently deployed at more than 3,500+ sites worldwide.

Lunit's growth trajectory received a substantial boost from a recent KRW166.50 billion post-IPO debt investment as of 07 May 2024. This capital injection underscores confidence in Lunit's promise to revolutionize cancer diagnostics globally, marking it as a compelling opportunity for investors interested in cutting-edge health tech.

Taxonomy: Medical AI, Cancer Screening, Radiology AI, Medical Imaging Software, Deep Learning Technology, Breast Cancer Screening, Chest X-ray AI, Mammography AI, Digital Breast Tomosynthesis, Medical Imaging Analysis, Healthcare AI, Biomarker Technology, AI-powered Diagnostics, Medical Data Analysis, Clinical Decision Support

Services & Products

Cancer Screening
Precision Oncology
AI-Driven Workflows
Medical Imaging Analysis
Clinical Decision Support

Target Customers

Healthcare Providers Radiologists Biopharma Companies Clinicians Oncology Researchers

Funding Rounds & Investors (11)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt •••••• - 07 May 2024
Post-IPO Equity •••••• - 15 Nov 2023
Post-IPO Equity •••••• - 24 Aug 2023
Venture Round •••••• 10
Investor Investor Investor Investor Investor Investor Investor Investor
•••• •••• 		29 Nov 2021
Series C •••••• 1 •••• •••• 19 Jul 2021

View All 11 Funding Rounds

Lunit Cancer Screening Alternatives & Competitors

Lunit Cancer Screening vs
Alinea Medical Imaging - a Rezolut partner
Alinea Medical Imaging - a Rezolut partner United States

A single image can save a life!

34 employees
Health Care, Medical Devices
Compare Lunit Cancer Screening vs Alinea Medical Imaging - a Rezolut partner
Lunit Cancer Screening vs
VM-Med
VM-Med Canada

A Private Multidisciplinary Healthcare Provider

43 employees
Health Care
Compare Lunit Cancer Screening vs VM-Med
Lunit Cancer Screening vs
contextflow
contextflow Austria

Comprehensive computer-aided detection software for lung cancer, ILD & COPD

Series A
33 employees
AI, Big Data
Compare Lunit Cancer Screening vs contextflow

FAQ About Lunit Cancer Screening

Lunit is a public company that develops medical AI software that helps conquer cancer globally.
Lunit Cancer Screening was founded in 2013.
Lunit Cancer Screening is headquartered in Seattle, United States.
Lunit Cancer Screening operates in the following industries: AI, Analytics, Computer Vision, Health Care, Medical Devices, Machine Learning.
Lunit Cancer Screening has approximately 343 employees.
Lunit Cancer Screening has completed 11 funding rounds, raising a total of $405.58B. The latest funding stage is Post Ipo Debt.
Lunit Cancer Screening offers: Cancer Screening, Precision Oncology, AI-Driven Workflows, Medical Imaging Analysis, Clinical Decision Support.
Top alternatives and competitors to Lunit Cancer Screening include Alinea Medical Imaging - a Rezolut partner, VM-Med, contextflow. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Lunit Cancer Screening and Alinea Medical Imaging - a Rezolut partner are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Lunit Cancer Screening and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy